Catalent Wins Fifth Consecutive European Outsourcing Award

Catalent Wins Fifth Consecutive European Outsourcing Award

Schorndorf controlled release facility upgrade minimizes customer impact, enhances productivity and reduces environmental impact

Somerset, NJ, October 17, 2012 – For the fifth consecutive year, Catalent Pharma Solutions was a winner at the prestigious European Outsourcing Awards, which run concurrently with the world’s largest annual pharma networking event, CPhI Worldwide, which was held from October 9-12 in Madrid, Spain.

The award, in the category ‘Most Improved Plant or Facility,’ was presented to Catalent for the redesign of its 221,000 sq ft site in Schorndorf Germany, which comprised an update of all air management systems within the entire controlled release facility, an increase in manufacturing capacity and optimised material flows. Catalent’s previous winning entries at the European Outsourcing Awards have included “Most Effective Scale-Up/Tech Transfer” in 2011 and “Best Contract Manufacturing Project” in 2008, 2009 and 2010.

In assessing the entries, the judging panel assessed criteria such as application of new technology, originality, quality standards and flexibility/adaptability.

“When the site was originally constructed in 1996, the air handling system was designed to create over-pressure manufacturing suites, however best practice is now to couple over pressure corridors with under pressure manufacturing suites,” explained Eric Schmidhäuser, Managing Director, Catalent Germany Schorndorf GmbH. “The new ‘clean corridor’ design helps reduce particulate entry at an earlier stage, enabling future cGMP compliance and reducing the potential for cross contamination.”

As a result of increased customer demand, Catalent also needed additional manufacturing capability and installed three fluid-bed granulators with a capacity of up to 600kg. A further phase of the project involved the reassessment of materials flow at the Schorndorf facility, resulting in reductions in cycle times and waste processes.

Schmidhäuser concluded, “Catalent continues to make strong investments in drug development expertise, new drug delivery technologies and site specific technology and supply capabilities across the globe. The project at Schorndorf is part of this ongoing programme and we are very pleased to receive this high profile industry recognition.”

About Catalent

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products.  With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J.

more products. better treatments. reliably supplied.™